Regeneron Pharmaceuticals (REGN) is returning from the Thanksgiving break with a hole in its drug research pipeline following the failure of the experimental eye drug nevascumab.

Across two mid-stage clinical trials, the addition of nevascumab to Eylea, Regeneron’s flagship product, failed to improve vision compared to Eylea alone, the company said Monday. The two studies were conducted in patients with diabetic macular edema and wet age-related macular degeneration. Based on these results, Regeneron and its development partner Bayer will not conduct phase 3 clinical trials of nevascumab.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.